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Abstract
The prescription of growth hormone therapy for children 
who are not growth hormone deficient is one of the 
controversies in contemporary paediatric endocrinology. 
Is it morally appropriate to enhance the growth, by 
means of medical treatment, of a child with idiopathic 
short stature? The medicalmorale and philosophical 
questions in this area are many. Data on the effects of 
human growth hormone (hGH) treatment will not on 
their own provide us with answers, as these effects have 
to be evaluated from a normative perspective. In this 
article we consider hGH treatment for children of 
idiopathic short stature from three normative 
perspectives: the goals of medicine, the good of the 
patient, and the public good. We argue that the 
prevention of psychological and social problems due to 
short stature (and not merely the enhancement of 
growth) should be the ultimate goal of medical treatment 
and research.
Introduction
The controversy around expanded use of human 
Growth Hormone (hGH) has arisen since it became 
possible to produce hGH by recombinant DNA 
technology.1 Before biosynthetic hGH became avail­
able in 1985, children were treated with natural 
growth hormone, extracted in very small amounts 
from the pituitary glands of cadavers. Given the 
limited supply of growth hormone, it was considered 
evident that only patients with established growth 
hormone deficiency should be treated with this 
hormone. Moreover, the criteria used to define 
growth hormone deficiency were rather restrictive.2
Now that the supply of synthetic hGH is -  at least 
technically -  unlimited, this situation has changed. It 
appears no longer necessary to restrict treatment to 
undisputed cases of growth hormone deficiency. 
First, the availability of hGH has led to a relaxation 
of criteria defining GH-insufficiency.3 Second, since 
hGH became available in larger quantities, growth
hormone has been prescribed for children with short 
stature that is not caused by growth hormone 
defiency but other conditions such as Turner’s 
syndrome and renal failure.
In this paper we will concentrate on the treatment 
of children with idiopathic short stature. Idiopathic 
short stature implies that there is not (yet) a specific 
dysfunction diagnosed as the cause of abnormal 
growth. The question arises whether it is morally 
appropriate that physicians give medical treatment 
to people who do not have a diagnosed disease: is the 
administration of growth hormone for idiopathic 
short children morally justifiable?
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Evaluation o f effectiveness o f  hG H  
therapy
Many discussions on the acceptability of growth 
hormone treatment for children without established 
growth hormone deficiency focus on the effectiveness 
of the intervention. Growth hormone therapy may 
stimulate growth. North American and European 
trials have demonstrated that hGH therapy improves 
growth velocity for at least a period of three years.4 
For example, in a study by the US Genentech 
Collaborative Study Group, which included children 
between five and ten years of age with 2*5 standard 
deviations below average height, the mean growth 
velocity increased from 4*6 cm/year to 8-0, 7-6, and 
7*2 cm/year in the first three treatment years. 
Predicted adult height improved from —2*7 to —1*6 
standard deviations from the mean.5
The effects of hGH on final height are less clear, 
as most studies do not include an untreated control 
group. Notably, the inclusion of placebo controls is 
generally deemed morally inadmissable.6 Further­
more, the acceleration of puberty caused by growth 
hormone therapy results in an extra advancement of 
skeletal age, which has a negative effect on final 
height. In a study by the Dutch Growth Hormone 
Working Group the final height of 12 GH-treated 
idiopathic short subjects has been compared to the 
final height of untreated “retrospective” controls. 
Final height of the hGH-treated children 
(159*2±8*0 cm, or ~2-6± l-0  SDS) turned out to 
be similar to that of untreated controls.7 On the 
basis of such outcomes, some would consider hGH
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treatment inappropriate for children with idiopathic 
short stature. On the other hand, some researchers 
in endocrinology conceive of these outcomes as 
reasons for further research. They suggest that the 
effectiveness of hGH therapy could be improved by 
refining the criteria for responsiveness to growth 
hormone. Furthermore, by combining hGH therapy 
with hormone treatment which will delay die onset 
of puberty, the final height of children could be 
further enhanced.7 So, ongoing endocrinological 
research may result in an improved efficacy of hGH 
therapy for at least specific groups of children with 
idiopathic short stature.
But if the effectiveness of hGH-therapy can be 
improved for some children with idiopathic short 
stature* does this imply that such therapy is morally 
justified? Data on effects of a therapy do not as such 
provide doctors and scientists with practical direc­
tives. The established fact that a drug has certain 
effects in some people does not imply the ethical 
conclusion that the prescription of that drug for 
those people is morally appropriate. Effects must be 
evaluated from a normative perspective in order to 
imply practical conclusions for clinical medicine. In 
the context of the physician-patient relationship, the 
dominant moral value is the individual patient’s 
good. Effects will be assessed as possible benefits 
and harms for the patient concerned. For a large 
part this evaluation is to be made by the patient 
him/herself. Nevertheless, this patient-related per­
spective cannot provide the sole basis for answering 
the question whether it is appropriate to offer treat­
ment to a whole group of people. Even more, one 
patient's assessment cannot answer the question 
whether refinement of growth hormone therapy for 
idiopathic short stature is important enough for the 
advancement of medical science and practice to 
merit experimental treatment. Here the goals of 
medicine itself are at stake. Certainly, the individual 
patient’s assessment has little or no bearing on the 
question whether idiopathic short stature is at all to 
be considered a medical condition in need of 
medical intervention. Probably, it is not just one’s 
short stature which may cause suffering, but 
society's negative attitudes towards short people. 
Before medicalising a social problem, we should 
evaluate whether such medicalization fits our ideals 
of a good society. In the next three sections, the 
justifiability of hGH treatment will be addressed 
from these three normative perspectives: the goals of 
medicine, the patient's good and the good of society.
hGH therapy and the goals o f  m edicine
Do the objectives of hormone therapy fit in with the 
overall goals of medical science and health care 
practice? What are these overall objectives anyway? 
Some caution is warranted here. One should not 
have the illusion that the goals of medical science 
and practice may be easily circumscribed. Further­
more, if it is possible to describe or to define objec­
tives of medicine, these will be constantly put into 
question by new technologies and possibilities. 
Incoherence between accepted goals and actual 
practice should serve as a starting point for critical 
medico-philosophical and ethical reflection. This 
may not only lead to adjustment of practice, but also 
to adjustment of the overall goals.
Theoretical perspectives
A rather general description is that medicine aims at 
the prevention and elimination of disease, the relief 
of suffering due to disease and the restoration of 
health. Whether the goal of hGH therapy for 
children with idiopathic short stature fits this overall 
objective depends on whether idiopathic short 
stature is a disease and whether growth enhance­
ment fosters health. But there are diverse theoretical 
perspectives on the concepts of health and disease. 
One may distinguish analytical and holistic perspec­
tives on health and disease.8 Analytical theories take 
“disease“ to be the basic concept, and they define 
health in terms of (absence of) disease. For example, 
Boorse’s biostatistical theory considers disease to be 
an internal state that interferes with (biostatistical) 
normal functions of organs or mental faculties.9 In a 
holistic theory, on the other hand, health is viewed as 
the basic concept and disease is defined in terms of 
health, that is, a disease is a bodily or mental process 
which tends to compromise health. In Nordenfelt’s 
holistic theory, health is defined as the ability of a 
person to realise under standard circumstances all 
the goals necessary for his minimal happiness.10
Notwithstanding the significant differences 
between both perspectives on the nature of health 
and disease, it is difficult to count idiopathic short 
stature as a disease in either of these two views. As 
mentioned, from the perspective of (analytical) bio­
statistical theory, a condition is called a disease if an 
organ’s function is subnormal:
“Whether a man is healthy or diseased . . .  is a com­
pletely objective affair. The tasks are to find the 
specific goals of the bodily organs and mental facul­
ties, to calculate the average contribution of these 
organs in the attainment of the goals, and to study 
whether a particular organ fulfils this average 
requirement.”11
Though bodily length of persons with idiopathic 
short stature is far below average levels, the condi­
tion is characterised by the absence of knowledge of 
biostatistical subfunctioning organs. A person’s short 
stature may simply be considered as fitting within a 
broader defined normal variance in stature within a 
population. As long as no subnormal functioning 
bodily organs or mental faculties have been discov­
ered, the term “disease” seems to be inappropriate 
from a biostatistical perspective.
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InNordenfelt’s holistic approach, idiopathic short 
stature counts as a disease if it tends to compromise 
health, that is, a person’s ability to realise minimal 
happiness. Recent psychological research shows that 
very short adolescents and aduits have a significantly 
greater risk for psychological, cognitive and sexual 
problems.1213 These problems related to short 
stature may indeed lead to a person being unable to 
realise minimal happiness. But these observations 
also shift the attention from the limited growth as 
such to the mental and psychosocial consequences 
of short stature. Rather than shortness being a 
disease in need of hGH therapy, the correllated psy­
chological, cognitive, and sexual risks call for appro­
priate preventive intervention. Obviously, it is not 
clear whether hGH qualifies as the appropriate 
therapy.
These theoretical disputes are mirrored by the 
practical controversy among endocrinologists about 
when to prescribe growth hormone. One group of 
physicians, sometimes labelled as "traditionalists”, 
holds to diagnostic criteria of growth hormone defi­
ciency, based on threshold blood levels of growth 
hormone. In this approach the diagnosed disease, 
defined as abnormal functioning of bodily organs, is 
central.14 These “traditionalists”5 face the problem 
that there are no highly specific and sensitive diag­
nostic tests for growth hormone deficiency. Others 
emphasise that indications for prescription of hGH 
therapy should be determined by criteria such as the 
severity of disability resulting from short stature, the 
expectation of psychosocial and/or functional 
benefit, and proven responsiveness to therapy.3 
Though disability due to short stature implicitly may 
have been the major target for hGH therapy, this has 
not yet been manifested in consensus on prescription 
criteria, nor has it directed the focus of medical 
research to the (psychosocial) consequences of short 
stature.
U ltim ate objective
If it is accepted that the ultimate objective of growth 
hormone treatment is to reduce the risk of psychoso­
cial disability, and that the objective of enhancing 
growth is a means to that goal, then hGH therapy 
may fit the formulation of the goals of medicine 
provided earlier. But evidently, the next question 
will be whether hGH treatment is the most appro­
priate means to that end. Consequently, medical 
research with hGH treatment should focus on the 
effects on psychological wellbeing rather than on 
growth as such. Even more importantly, scientists 
should study whether psychological problems may 
be better addressed and prevented by psychological 
interventions and support.
Within the context of clinical practice, the inter­
mediate conclusion can be that, if growth hormone 
therapy is considered as a means to reduce the risks 
of mental and social problems, then these aspects of
wellbeing also need to be explicitly looked at. For 
that reason, hGH treatment of small persons should 
not be an isolated therapy, but should be combined 
with pyschological care and counselling.
hGH and the patient’s good
If hGH therapy is considered as an appropriate 
medical intervention, which fits the objectives of 
medicine and health care, a crucial question will 
become whether this therapy serves the individual 
patient's good. In order to answer this question, 
effects must be assessed in terms of harms and 
benefits for the patient.
Possible benefits of growth hormone therapy 
include a chance of extra growth and perhaps a 
reduced risk for psychological problems. The 
burdens of treatment concern daily injections for a 
period of several years. The impact of daily invasive 
treatment on a young child and on family life 
should not be underestimated. There is a possibil­
ity that such a treatment may induce psychological 
problems. The child who realises that the daily 
injections are for the sake of growth, may develop a 
strong conviction that normal stature is extremely 
important. As the effects of treatment are limited, 
there is a chance that the child will suffer from a 
large discrepancy between her ideal and her actual 
stature. On the other hand, the risks of physical 
harm caused by hGH treatment, appear to be 
remarkably small.1415 Most serious is a reported 
increase in incidence of leukaemia during hG H  
treatment of GH-deficient patients. Boose et al 
found a higher incidence of leukaemia in the popu­
lation of children treated with GH (5:100,000) 
than in the age-related normal population of 
children (2:100,000), but strong evidence that GH 
therapy may induce leukaemia has not yet been 
found.16
How should these benefits and harms be weighed? 
As people have divergent views on the evaluation of 
risk, pain, health and medicine, the patient’s own 
perspective is most relevant for weighing her benefits 
and harms. Probably, for many people the benefits 
of growth hormone treatment will not weigh up to 
the trouble it involves. For example, one person may 
focus on the prevention of disability in psychological 
functioning and he may think that the chances of 
effective prevention by growth hormone therapy are 
remote. But another person may focus on the growth 
as such, and give less weight to the psychological 
issue. For her, growth may be one of the most 
important issues in her life, and she may accept 
going through a lot of trouble in order to increase the 
chance to improve growth, even if she will gain only 
a few extra centimetres. Furthermore, for many 
people it is important that they have tried every 
option which may ameliorate their condition. So, 
even if in the end the results of treatment are disap­
pointing, a person may be glad she has taken the
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opportunity of growth hormone treatment -  or at 
least she may still be convinced that her choice for 
treatment was a good choice. Consequently, con­
sidered from the perspective of the patient’s own 
good, hGH treatment may well be evaluated as 
acceptable in individual cases. Even if the medical 
value of hGH therapy is controversial, a patient may 
come to the conclusion that the burdens of growth 
hormone therapy are not overly heavy. The physi­
cian has the obligation to explain possible effects and 
side effects, in order to enable the patient to come to 
an autonomous choice.
However, in many cases of idiopathic short 
stature the patient’s perspective on her own good 
will be difficult to grasp. Often, the children 
involved will only be six years of age. In those and 
other cases it is not the children themselves but 
their parents who seek treatment. Naturally, if the 
parents weigh the benefits and harms of growth 
hormone therapy, they will be led by their own 
ideals of how a child should be. But the ideal 
picture parents have of their child does not neces­
sarily represent the best interests of this child, if 
only because many children end up not fulfilling 
their parents’ ideal picture.
Is a proxy consent of the parents in this context a 
sufficient substitute for an autonomous decision of 
the patient herself? We think that proxy consent 
can be sufficient if the physician agrees with the 
parents that hGH therapy could be beneficial to the 
child, and if he is certain that the parents’ expecta­
tions of the therapy are reasonable. Therefore, it is 
important that doctor as well as parents focus on 
the child’s overall wellbeing rather than on growth 
alone.
Above all, the child’s own assessment of the 
therapy and its goals should not too easily be over­
looked« Even though many children of five or six 
years of age will not be able to grasp and evaluate all 
relevant consequences of a decision to accept or 
forgo treatment, parents and physician may get an 
idea to what extent the child considers its short 
stature to be a problem. Furthermore, if treatment is 
started, the child’s evaluation of the burdens of 
therapy can and should be carefully monitored. If 
the child considers the daily injection as burden­
some, then doctor and parents have a good reason to 
stop hG treatment.
hG H  therapy and the good o f society
A third normative framework for evaluating the 
appropriateness of growth hormone therapy for 
children with idiopathic short stature concerns the 
public good. At least three types of moral considera­
tions are relevant: consideradons of justice, of 
medicalization and of stigmatisation.
First, there is the question of allocation of 
resources. Expanded use of growth hormone implies 
expanded costs for health care. Growth hormone
therapy for a child with idiopathic short stature takes 
several years, the treatment is expensive and the 
effectiveness in terms of predicted adult height is 
minimal. Even when new techniques enhance the 
effectiveness of hGH therapy, one should face the 
question whether growth hormone therapy for 
children of idiopathic short stature can be morally 
justified in times of scarce health care resources.17 
We will not elaborate this problem further, as we 
think that the problem of justice should not be dealt 
with before the moral acceptability of the therapy 
itself has been determined.
M edicalization
A second concern is that expanded use of growth 
hormone may result in a medicalization of the 
phenomenon of short stature. Medicalization can 
be defined as the social process wherein medical 
terms become relevant for more and more phe­
nomena of daily life.18 Medicalization processes 
may be criticised from a moral point of view when 
they result in a growing dependence of groups of 
people on the medical professions. Medicalization 
turns people into patients. This is not necessarily a 
problem for the individual short person who is 
asking for medical care. But a society which holds 
autonomy and independence as important ideals, 
may be cautious in declaring a physical condition a 
disease if it does not necessarily result in suffering. 
Nevertheless, moral objections to medicalization 
become less relevant in cases where the interven­
tions aim at a reduction of psychological and social 
risks of short stature, rather than at enhancement 
of growth as such. After all, these risks are not 
trivial, and medical and psychological interventions 
may have beneficial effects for the persons con­
cerned.
However, from the perspective of a good society, 
the emphasis on psychological and social wellbeing 
of short persons is not without moral problems 
either. One may argue that the psychological and 
social problems concerned will at least in part be 
caused by the societal prejudices concerning short 
stature. Short people are easily overlooked -  in the 
literal and figurative sense. They may be stigma­
tised as abnormal and unimportant. Adults of 150 
cm height are constantly confronted with the fact 
that the physical and social world in which they live 
is not adapted to people of their length. If their 
problems are indeed caused by social factors, then 
one may argue that interventions should not be 
directed at the short people, but first of all at 
society. As long as interventions focus on short 
people and not on society, the cultural stigma of 
shortness being abnormal and problematic, is rein­
forced.
In our opinion, these considerations offer highly 
important reasons for public policies and private 
initiatives against social prejudice, but they do not
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justify abstaining from medical care for the indi­
vidual persons concerned. First of all, short people 
may find more concrete benefit in medical and psy­
chological care than in public attempts to change 
social attitudes. For that reason, secondly, the 
parents of short children should not be morally 
blamed if they choose medical treatment in the hope 
of reducing certain risks, rather than heroically 
offering resistance to society’s prejudices. Finally, if 
a physician is confronted with parents who worry 
about the wellbeing of their small child, he ought to 
concentrate on the wellbeing of this concrete 
patient. The battle against social prejudice is 
important, but it is, in this context, not the primary 
obligation of the physician.
Conclusion
Is the administration of hGH for children with idio­
pathic short stature morally justified? If the goal of 
this therapy is simply to enhance bodily stature then 
this question should be answered negatively from 
both the medical perspective and the perspective of a 
good society. The enhancement of bodily growth is a 
controversial objective of any medical therapy or 
research, especially as long as no physiological 
causes of limited growth have been discovered. After 
all, in a normal and healthy population there will 
always be persons with extremely short stature (and, 
for that matter, there will be persons with extremely 
long stature as well).
Interventions are appropriate if their ultimate goal 
is not just to enhance growth as such, but rather to 
reduce the risks of psychological and social problems. 
Growth hormone therapy may be part of the medical 
strategy to reduce these risks. If so, it should be 
accompanied by a careful monitoring of the psycho­
logical and social wellbeing of the child, and by 
psychological counselling.
This shift in treatment objectives also has conse­
quences for medical research programmes. If 
enhancement of growth is considered as one of the 
means to protect the patient’s social and psychologi­
cal wellbeing, endocrinological research on hGH 
therapy should focus on these latter effects, rather 
than on gaining extra centimetres. Even more 
importantly, the positive and negative effects on 
wellbeing of endocrinological interventions should 
be compared with the effects of other strategies to 
protect wellbeing. The development and evaluation 
of strategies for psychological support of very short 
children deserves more attention.
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